3T Biosciences poaches Kite exec to head clinical operations

California-based immunotherapy company 3T Biosciences has appointed Rebeca Villarreal-Barragan as head of clinical operations. In this role, Ms Villarreal-Barragan will lead all aspects of clinical operations as the company advances its pipeline of T-cell receptor (TCR)-based therapeutics for solid tumors.

“Rebeca brings a strong track record of building and leading clinical operations in both established biopharma organizations and emerging biotechnology companies,” said Dr Behzad Kharabi, chief medical officer of 3T Biosciences, adding: “Her pragmatic, quality-focused approach and experience delivering complex early phase clinical trials will be an important asset as we progress our pipeline of TCR-based therapeutics for solid tumors into the clinic, and ultimately to patients in need.”

“Clinical execution and aligning clinical delivery with scientific strategy, timelines, and capital efficiency are critical to delivering 3T’s breakthrough medicines for the treatment of solid tumors to patients,” said Ms Villarreal-Barragan. “I’m excited to join the team and to work across functions to support the execution of high-quality clinical trials,” she added.